Literature DB >> 35058607

CDK4/6-USP51 axis regulates lung adenocarcinoma metastasis through ZEB1.

Jianjun Li1, Xuechun Xiao1, Hang Wang1, Wenhao Wang1, Yang Ou1, Zhaoyang Wang1, Huimin Jiang1, Yuxin Liu1, Zhen Zhang2, Shuang Yang3.   

Abstract

USP51 is a member of the deubiquitinase (DUB) family that participates in many pathophysiological processes. However, the aberrant expression and biological function of USP51 in cancer progression remain largely unclear. In this study, we demonstrated that USP51 is overexpressed in metastatic human lung adenocarcinoma and patients with high USP51 expression in their tumors have shorter overall survival than those with low expression of USP51. Moreover, we showed that USP51 promotes tumor metastasis and invasion through regulating ZEB1, which is a key transcriptional factor that induces the malignant progression of lung adenocarcinoma. In terms of molecular mechanism, USP51 is phosphorylated and activated by CDK4/6, thus resulting in the deubiquitination and stabilization of ZEB1 protein. Of note, we also confirmed that the expression of p-RB (an indicator of CDK4/6 activity), p-USP51 and ZEB1 are significantly positively correlated in human lung adenocarcinoma samples. In conclusion, these findings revealed that the CDK4/6-USP51-ZEB1 signaling pathway is a driver of lung adenocarcinoma metastasis, which could be a potential therapeutic strategy for the treatment of malignant tumors.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35058607     DOI: 10.1038/s41417-021-00420-7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  42 in total

Review 1.  Breaking the chains: structure and function of the deubiquitinases.

Authors:  David Komander; Michael J Clague; Sylvie Urbé
Journal:  Nat Rev Mol Cell Biol       Date:  2009-08       Impact factor: 94.444

2.  [Trends in incidence of lung cancer according to histological subtype among men and women in Germany : Analysis of cancer registry data with the application of multiple imputation techniques].

Authors:  Dorothee Twardella; Karla Geiss; Martin Radespiel-Tröger; Axel Benner; Joachim H Ficker; Martin Meyer
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2018-01       Impact factor: 1.513

3.  The Deubiquitinating Enzyme USP7 Regulates Androgen Receptor Activity by Modulating Its Binding to Chromatin.

Authors:  Shu-Ting Chen; Maiko Okada; Ryuichiro Nakato; Kosuke Izumi; Masashige Bando; Katsuhiko Shirahige
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

4.  Treatment of lung adenocarcinoma brain metastases: what is the role of radiotherapy in the age of precision medicine?

Authors:  Elizabeth J Buss; Tony J C Wang
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 5.  Lung Cancer Pathology: Current Concepts.

Authors:  William D Travis
Journal:  Clin Chest Med       Date:  2020-01-02       Impact factor: 2.878

Review 6.  Spectrum of Lung Adenocarcinoma.

Authors:  Barry D Hutchinson; Girish S Shroff; Mylene T Truong; Jane P Ko
Journal:  Semin Ultrasound CT MR       Date:  2018-11-30       Impact factor: 1.875

7.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 8.  Deubiquitinases in cancer: new functions and therapeutic options.

Authors:  J M Fraile; V Quesada; D Rodríguez; J M P Freije; C López-Otín
Journal:  Oncogene       Date:  2011-09-26       Impact factor: 9.867

9.  Robotic lobectomy for lung cancer: initial experience of a single institution in Korea.

Authors:  Seha Ahn; Jin Yong Jeong; Hyung Woo Kim; Joong Hyun Ahn; Giyong Noh; Soo Seog Park
Journal:  Ann Cardiothorac Surg       Date:  2019-03

Review 10.  Breaking the chains: deubiquitylating enzyme specificity begets function.

Authors:  Michael J Clague; Sylvie Urbé; David Komander
Journal:  Nat Rev Mol Cell Biol       Date:  2019-06       Impact factor: 94.444

View more
  1 in total

1.  POLD2 is activated by E2F1 to promote triple-negative breast cancer proliferation.

Authors:  Zhen Zhang
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.